Your browser doesn't support javascript.
loading
Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer : Alexandra Leary.
Leary, Alexandra; Estévez-García, Purificación; Sabatier, Renaud; Ray-Coquard, Isabelle; Romeo, Margarita; Barretina-Ginesta, Pilar; Gil-Martin, Marta; Garralda, Elena; Bosch-Barrera, Joaquim; Morán, Teresa; Martin-Martorell, Paloma; Nadal, Ernest; Gascón, Pere; Rodon, Jordi; Lizcano, Jose M; Muñoz-Guardiola, Pau; Fierro-Durán, Gemma; Pedrós-Gámez, Oriol; Pérez-Montoyo, Héctor; Yeste-Velasco, Marc; Cortal, Marc; Pérez-Campos, Antonio; Alfon, Jose; Domenech, Carles; Pérez-Fidalgo, Alejandro; Oaknin, Ana.
Afiliação
  • Leary A; Medical Oncology, Institut Gustave Roussy, Villejuif, France.
  • Estévez-García P; Medical Oncology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  • Sabatier R; Department of Medical Oncology, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, Marseille, France.
  • Ray-Coquard I; Medical Oncology, Centre Léon Bérard, Lyon, France.
  • Romeo M; Department of Medical Oncology, Department of Medicine, Institut Català d'Oncologia Badalona Hospital Germans Trias i Pujol, Badalona-Applied Research Group in Oncology, Germans Trias i Pujol Institute, Universitat Autònoma de Barcelona, Badalona, Spain.
  • Barretina-Ginesta P; Medical Oncology Department, Precision Oncology Group (OncoGIR-Pro) Girona Biomedical Research Institute (IDIBGI) and Department of Medical Sciences, Institut Català d'Oncologia (ICO), Medical School University of Girona (UdG), Girona, Spain.
  • Gil-Martin M; Medical Oncology, Catalan Institute of Oncology and IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain.
  • Garralda E; Medical Oncology Service, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Bosch-Barrera J; Medical Oncology Department, Precision Oncology Group (OncoGIR-Pro) Girona Biomedical Research Institute (IDIBGI) and Department of Medical Sciences, Institut Català d'Oncologia (ICO), Medical School University of Girona (UdG), Girona, Spain.
  • Morán T; Department of Medical Oncology, Department of Medicine, Institut Català d'Oncologia Badalona Hospital Germans Trias i Pujol, Badalona-Applied Research Group in Oncology, Germans Trias i Pujol Institute, Universitat Autònoma de Barcelona, Badalona, Spain.
  • Martin-Martorell P; Medical Oncology, INCLIVA-Hospital Clínico Universitario, Valencia, Spain.
  • Nadal E; Medical Oncology, Catalan Institute of Oncology and IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain.
  • Gascón P; Medical Oncology Service, Hospital Clínic. Universitat de Barcelona, Barcelona, Spain.
  • Rodon J; Early Drug Development, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
  • Lizcano JM; Department of Biochemistry and Molecular Biology, Institut de Neurocièncias, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Barcelona, Spain.
  • Muñoz-Guardiola P; Protein Kinases in Cancer Research, Vall Hebron Institut de Recerca (VHIR), Barcelona, Spain.
  • Fierro-Durán G; Department of Biochemistry and Molecular Biology, Institut de Neurocièncias, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Barcelona, Spain.
  • Pedrós-Gámez O; Research and Development, Ability Pharmaceuticals, Cerdanyola del Vallès, Barcelona, Spain.
  • Pérez-Montoyo H; Research and Development, Ability Pharmaceuticals, Cerdanyola del Vallès, Barcelona, Spain.
  • Yeste-Velasco M; Research and Development, Ability Pharmaceuticals, Cerdanyola del Vallès, Barcelona, Spain.
  • Cortal M; Research and Development, Ability Pharmaceuticals, Cerdanyola del Vallès, Barcelona, Spain.
  • Pérez-Campos A; Research and Development, Ability Pharmaceuticals, Cerdanyola del Vallès, Barcelona, Spain.
  • Alfon J; Research and Development, Ability Pharmaceuticals, Cerdanyola del Vallès, Barcelona, Spain.
  • Domenech C; Research and Development, Ability Pharmaceuticals, Cerdanyola del Vallès, Barcelona, Spain.
  • Pérez-Fidalgo A; Research and Development, Ability Pharmaceuticals, Cerdanyola del Vallès, Barcelona, Spain.
  • Oaknin A; Research and Development, Ability Pharmaceuticals, Cerdanyola del Vallès, Barcelona, Spain. carles.domenech@abilitypharma.com.
BMC Cancer ; 24(1): 911, 2024 Jul 29.
Article em En | MEDLINE | ID: mdl-39075404
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article